NCT00579254

Real Life Experience With Caduet In Patients With Cardiovascular Risk Factors

Real Life Experience With Caduet Evaluating Effectiveness, Safety and Tolerability in the Management of Cardiovascular Risk Factors (EXCEL Study)

• Status: Terminated
• Phase: —
• Study type: Observational
• Enrollment: 112 (actual)
• Sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc. · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

To assess the effect of single pill therapy on the management of hypertension and other cardiovascular risk factors (e.g., dyslipidemia) in Indian patients in whom the treating doctor has already considered that the administration of the amlodipine/atorvastatin single pill to be appropriate

Detailed description

Patients who have been prescribed single pill Caduet are eligible to participate in this study. The treating physician will obtain written informed consent from each subject or the subject's legally acceptable representative before any study-specific activity is performed. The study terminated on May 5, 2008. The decision to terminate was due to inability to achieve study timelines and undue delay in obtaining IEC/IRB permission at some sites. No safety or efficacy issues caused the decision to terminate.

Conditions

• Hypertension and Cardiovascular Risk Factors

Interventions

Type	Name	Description
DRUG	CADUET (AMLODIPINE 5 mg/ATORVASTATIN 10 mg or 20 mg)	Patients who have been treated with Caduet 5/10 or 5/20 mg single pill treatment, based on their clinical conditions and latest locally approved packet insert recommendations will be eligible to be enrolled to this study

Timeline

• Start date: 2007-12-01
• Primary completion: 2008-05-01
• Completion: 2008-05-01
• First posted: 2007-12-24
• Last updated: 2021-01-28
• Results posted: 2009-06-19